UNDERWRITING AGREEMENT $5,775,000 9.25% Series A Cumulative Redeemable Perpetual Preferred Shares SKYLIGHT HEALTH GROUP INC. (incorporated under the Canada Business Corporations Act )Underwriting Agreement • December 7th, 2021 • Skylight Health Group Inc. • Services-offices & clinics of doctors of medicine • New York
Contract Type FiledDecember 7th, 2021 Company Industry JurisdictionSkylight Health Group Inc., a company incorporated under the Canada Business Corporations Act (the “Company”), proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters”) for whom The Benchmark Company, LLC is acting as representative (the “Representative”), with respect to (i) the sale by the Company and the purchase by the Underwriters, acting severally and not jointly, of the respective number of shares of 9.25% Series A Cumulative Redeemable Perpetual Preferred Stock (each, a “Firm Share”), no par value, of the Company set forth on Schedule I hereto (the “Preferred Shares” or “Shares”) and (ii) the grant by the Company to the Underwriters, acting severally and not jointly, of the option described in Section 2(b) hereof to purchase all or any part of additional shares of Series A Preferred Stock representing 15% of the Series A Preferred Stock set forth on Schedule I hereto (the “Option Shares”). The Firm Shares and the Option Shares are collectively
UNDERWRITING AGREEMENT 13,333,334 Common Shares AURINIA PHARMACEUTICALS INC. (incorporated under the Business Corporations Act (Alberta))Underwriting Agreement • July 23rd, 2020 • Aurinia Pharmaceuticals Inc. • Pharmaceutical preparations • New York
Contract Type FiledJuly 23rd, 2020 Company Industry JurisdictionAurinia Pharmaceuticals Inc., a company incorporated under the Business Corporations Act (Alberta) (the “Company”), proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters”) for whom Jefferies LLC (“Jefferies”) and SVB Leerink LLC (“SVB Leerink”) are acting as the representatives (the “Representatives”), an aggregate of 13,333,334 common shares (each, a “Firm Share”), no par value, of the Company (the “Common Shares”). The Company also proposes to grant to the Underwriters an option to purchase up to 2,000,000 additional Common Shares (the “Option Shares” and, together with the Firm Shares, the “Shares”).
UNDERWRITING AGREEMENT 11,115,165 Common Shares AURINIA PHARMACEUTICALS INC. (incorporated under the Business Corporations Act (Alberta))Underwriting Agreement • December 10th, 2019 • Aurinia Pharmaceuticals Inc. • Pharmaceutical preparations • New York
Contract Type FiledDecember 10th, 2019 Company Industry JurisdictionAurinia Pharmaceuticals Inc., a company incorporated under the Business Corporations Act (Alberta) (the “Company”), proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters”) for whom Jefferies LLC (“Jefferies”) and SVB Leerink LLC (“SVB Leerink”) are acting as the representatives (the “Representatives”), an aggregate of 11,115,165 common shares (each, a “Firm Share”), no par value, of the Company (the “Common Shares”). The Company also proposes to grant to the Underwriters an option to purchase up to 1,667,274 additional Common Shares (the “Option Shares” and, together with the Firm Shares, the “Shares”).
UNDERWRITING AGREEMENT 4,619,773 Common Shares and 4,619,773 Warrants ONCOLYTICS BIOTECH Inc. (incorporated under the Business Corporations Act (Alberta))Underwriting Agreement • August 16th, 2019 • Oncolytics Biotech Inc • Pharmaceutical preparations • New York
Contract Type FiledAugust 16th, 2019 Company Industry JurisdictionOncolytics Biotech Inc., a company incorporated under the Business Corporations Act (Alberta) (the "Company"), proposes to sell to the several underwriters named in Schedule I hereto (the "Underwriters") for whom Ladenburg Thalmann & Co. Inc. is acting as representative (the "Representative"), an aggregate of (i) 4,619,773 common shares (each, a "Firm Share"), no par value, of the Company (the "Common Shares"), and (ii) 4,619,773 Common Share purchase warrants (the “Firm Warrants”). The Company also proposes to grant to the Underwriters an option to purchase up to (i) 692,965 additional Common Shares (the "Option Shares" and, together with the Firm Shares, the "Shares"), and (ii) 692,965 additional warrants (the “Option Warrants” and together with the Firm Warrants, the “Warrants”). The common shares issuable upon exercise of the Firm Warrants and the Option Warrants are collectively referred to as the “Warrant Shares.” The Firm Shares, the Option Shares, the Firm Warrants, the Option
UNDERWRITING AGREEMENT 1,372,213 Common Shares ONCOLYTICS BIOTECH Inc. (incorporated under the Business Corporations Act (Alberta))Underwriting Agreement • June 1st, 2018 • Oncolytics Biotech Inc • Pharmaceutical preparations • New York
Contract Type FiledJune 1st, 2018 Company Industry JurisdictionOncolytics Biotech Inc., a company incorporated under the Business Corporations Act (Alberta) (the “Company”), proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters”) for whom Ladenburg Thalmann & Co. Inc. is acting as representative (the “Representative”), an aggregate of 1,372,213 common shares (each, a “Firm Share”), no par value, of the Company (the “Common Shares”). The Company also proposes to grant to the Underwriters an option to purchase up to 205,832 additional Common Shares (the “Option Shares” and, together with the Firm Shares, the “Shares”). To the extent there are no additional Underwriters listed on Schedule I hereto, the term “Representative” as used herein shall mean Ladenburg Thalmann & Co. Inc. as Underwriter and the term “Underwriters” shall be construed as singular.
UNDERWRITING AGREEMENT 22,300,000 Common Shares AURINIA PHARMACEUTICALS INC. (incorporated under the Business Corporations Act (Alberta))Underwriting Agreement • March 16th, 2017 • Aurinia Pharmaceuticals Inc. • Pharmaceutical preparations • New York
Contract Type FiledMarch 16th, 2017 Company Industry JurisdictionAurinia Pharmaceuticals Inc., a company incorporated under the Business Corporations Act (Alberta) (the “Company”), proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters”) for whom Leerink Partners LLC (“Leerink”) and Cantor Fitzgerald & Co. are acting as the representatives (the “Representatives”), an aggregate of 22,300,000 common shares (each, a “Firm Share”), no par value, of the Company (the “Common Shares”). The Company also proposes to grant to the Underwriters an option to purchase up to 3,345,000 additional Common Shares (the “Option Shares” and, together with the Firm Shares, the “Shares”).
8,667,000 Shares DHX MEDIA LTD. (incorporated under the Canada Business Corporations Act) Variable Voting Shares Common Voting Shares UNDERWRITING AGREEMENTUnderwriting Agreement • April 27th, 2016 • DHX Media Ltd. • Services-allied to motion picture distribution • Ontario
Contract Type FiledApril 27th, 2016 Company Industry JurisdictionDHX Media Ltd., a company continued under the Canada Business Corporations Act (the “Company”), proposes to sell to the several underwriters (the “Underwriters”) named in Schedule I hereto for whom Canaccord Genuity Corp. is acting as representative (the “Representative”), an aggregate of 8,667,000 shares of the Company (the “Firm Shares”), consisting of a combination of variable voting shares of the Company (the “Variable Voting Shares”) and common voting shares of the Company (the “Common Voting Shares”). The Company has also granted to the several Underwriters an option to purchase up to an aggregate of 1,300,050 additional shares of the Company, consisting of a combination of Variable Voting Shares and Common Voting Shares, on the terms and for the purposes set forth in Section 3 hereof (the “Option Shares”). The Firm Shares and any Option Shares purchased pursuant to this Underwriting Agreement are herein collectively called the “Securities.”
7,500,000 Common Shares TEKMIRA PHARMACEUTICALS CORPORATION (incorporated under the Business Corporations Act (British Columbia)) UNDERWRITING AGREEMENTUnderwriting Agreement • March 20th, 2015 • TEKMIRA PHARMACEUTICALS Corp • Pharmaceutical preparations • New York
Contract Type FiledMarch 20th, 2015 Company Industry JurisdictionTekmira Pharmaceuticals Corporation, a company incorporated under the Business Corporations Act (British Columbia) (the “Company”), proposes to sell to Leerink Partners LLC (“Leerink”), RBC Capital Markets, LLC (“RBC”) and each of the other Underwriters named in Schedule I hereto (collectively, the “Underwriters” which term shall also include any underwriter substituted as hereinafter provided in Section 10 hereof) for whom Leerink and RBC are acting as representatives (in such capacity, the “Representatives”), an aggregate of 7,500,000 common shares (the “Firm Shares”) of the Company (the “Common Shares”). The Company has also granted to the Underwriters an option to purchase up to an aggregate of 1,125,000 additional Common Shares, on the terms and for the purposes set forth in Section 3 hereof (the “Option Shares”). The Firm Shares and any Option Shares purchased pursuant to this Underwriting Agreement are herein collectively called the “Securities.”
3,750,000 Common Shares TEKMIRA PHARMACEUTICALS CORPORATION (incorporated under the Business Corporations Act (British Columbia)) UNDERWRITING AGREEMENTUnderwriting Agreement • March 13th, 2015 • TEKMIRA PHARMACEUTICALS Corp • Pharmaceutical preparations • New York
Contract Type FiledMarch 13th, 2015 Company Industry JurisdictionTekmira Pharmaceuticals Corporation, a company incorporated under the Business Corporations Act (British Columbia) (the "Company"), proposes to sell to the several underwriters (the "Underwriters") named in Schedule I hereto for whom Stifel Nicolaus & Company, Incorporated is acting as representative (the "Representative"), an aggregate of 3,750,000 common shares (the "Firm Shares") of the Company (the "Common Shares"). The Company has also granted to the several Underwriters an option to purchase up to an aggregate of 562,500 additional Common Shares, on the terms and for the purposes set forth in Section 3 hereof (the "Option Shares"). The Firm Shares and any Option Shares purchased pursuant to this Underwriting Agreement are herein collectively called the "Securities."
3,750,000 Common Shares TEKMIRA PHARMACEUTICALS CORPORATION (incorporated under the Business Corporations Act (British Columbia)) UNDERWRITING AGREEMENTUnderwriting Agreement • October 17th, 2013 • TEKMIRA PHARMACEUTICALS Corp • Pharmaceutical preparations • New York
Contract Type FiledOctober 17th, 2013 Company Industry JurisdictionTekmira Pharmaceuticals Corporation, a company incorporated under the Business Corporations Act (British Columbia) (the “Company”), proposes to sell to the several underwriters (the “Underwriters”) named in Schedule I hereto for whom Stifel Nicolaus & Company, Incorporated is acting as representative (the “Representative”), an aggregate of 3,750,000 common shares (the “Firm Shares”) of the Company (the “Common Shares”). The Company has also granted to the several Underwriters an option to purchase up to an aggregate of 562,500 additional Common Shares, on the terms and for the purposes set forth in Section 3 hereof (the “Option Shares”). The Firm Shares and any Option Shares purchased pursuant to this Underwriting Agreement are herein collectively called the “Securities.”
3,900,000 Shares NOVADAQ TECHNOLOGIES INC. (incorporated under the Canada Business Corporations Act) Common Shares UNDERWRITING AGREEMENTUnderwriting Agreement • May 2nd, 2013 • Novadaq Technologies Inc • Electromedical & electrotherapeutic apparatus • New York
Contract Type FiledMay 2nd, 2013 Company Industry JurisdictionNovadaq Technologies Inc., a company incorporated under the Canada Business Corporations Act (the “Company”), proposes to sell to Canaccord Genuity Inc. (the “Underwriter”), an aggregate of 3,900,000 common shares (the “Firm Shares”) of the Company (the “Common Shares”). The Company has also granted to the Underwriter an option to purchase up to an aggregate of 585,000 additional Common Shares, on the terms and for the purposes set forth in Section 3 hereof (the “Option Shares”). The Firm Shares and any Option Shares purchased pursuant to this Underwriting Agreement are herein collectively called the “Securities.”
6,100,000 Shares NOVADAQ TECHNOLOGIES INC. (incorporated under the Canada Business Corporations Act) Common Shares UNDERWRITING AGREEMENTUnderwriting Agreement • April 4th, 2012 • Novadaq Technologies Inc • Electromedical & electrotherapeutic apparatus • New York
Contract Type FiledApril 4th, 2012 Company Industry JurisdictionNovadaq Technologies Inc., a company incorporated under the Canada Business Corporations Act (the “Company”), proposes to sell to the several underwriters (the “Underwriters”) named in Schedule I hereto for whom Piper Jaffray & Co. and Stifel, Nicolaus & Company, Incorporated are acting as representatives (the “Representatives”), an aggregate of 6,100,000 shares (the “Firm Shares”) of common shares (the “Common Shares”), of the Company. The Company has also granted to the several Underwriters an option to purchase up to an aggregate of 915,000 additional shares of Common Shares, on the terms and for the purposes set forth in Section 3 hereof (the “Option Shares”). The Firm Shares and any Option Shares purchased pursuant to this Underwriting Agreement are herein collectively called the “Securities.”